Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 0.78 |
| ▸ | AXL | P30530 | 1/20 | 0.71 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5825644 | 0.95 | PDGFRA (0.90) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL5825878 | 0.92 | PDGFRA (0.85) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL5824600 | 0.92 | PDGFRA (0.84) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL12410631 | 0.90 | PDGFRA (0.82) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL1893637 | 0.89 | PDGFRA (0.80) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL1895949 | 0.89 | PDGFRA (0.80) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL8070553 | 0.89 | PDGFRA (0.94) | PDGFRAKITKDR | |
| SCHEMBL5825864 | 0.89 | PDGFRA (0.80) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL5824933 | 0.89 | PDGFRA (0.80) | PDGFRAKITKDRAXLFGFR2 | |
| SCHEMBL5824766 | 0.88 | PDGFRA (0.79) | PDGFRAKITKDRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404244-B2 | Pan-KIT kinase inhibitor having quinoline structure and application thereof | Tarapeutics Science Inc. (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20250186452-A1 | NOVEL USE OF QUINOLINE COMPOUND | Tarapeutics Science Inc. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4491181-A1 | NOVEL USE OF QUINOLINE COMPOUND | Tarapeutics Science Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| WO-2020118753-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-18 | — | — | WO | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | PDGFRA 1572/4885KIT 391/4885KDR 22/4885 |
| US-12404244-B2 | Pan-KIT kinase inhibitor having quinoline structure and application thereof | KIT, MAP3K7, ABL1 | PDGFRA 747/4885KIT 1/4885KDR 357/4885 |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRA 1/4885KIT 401/4885KDR 4/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | PDGFRA 1743/4885KIT 312/4885KDR 60/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRA 1/4885KIT 499/4885KDR 5/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | PDGFRA 1743/4885KIT 312/4885KDR 60/4885 |
| US-20250186452-A1 | NOVEL USE OF QUINOLINE COMPOUND | ARG1, MSR1, SLC11A2 | PDGFRA 2224/4885KIT 476/4885KDR 1464/4885 |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | KIT, MAP3K7, ABL1 | PDGFRA 747/4885KIT 1/4885KDR 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.